The FDA accepted the New Drug Application filed by Intercept Pharmaceuticals for obeticholic acid, which is indicated as a treatment for fibrosis as a result of non-alcoholic steatohepatitis. The filing was granted Priority Review status, and a PDUFA action date was set for March 26.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.